Europe Systemic Aspergillosis and Systemic Candidasis Market
Published On: Mar 2021
Published On: Mar 2021
According to the latest study on ‘Europe Systemic Aspergillosis and Systemic Candidasis Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class, Route of Administration, Distribution Channel, and Country,’ the Europe Systemic Aspergillosis and Systemic Candidasis market was valued at US$ 1,702.60 million in 2019 and is projected to reach US$ 2,237.55 million by 2027; it is expected to grow at a CAGR of 3.5% during 2020–2027. The report highlights the trends prevailing in the Europe systemic aspergillosis and systemic candidasis market and the factors driving the market along with those that act as deterrents to its growth.
Based on type, the systemic aspergillosis and systemic candidasis market is segmented voriconazole, liposomal, amphotericin B, systemic oral azoles, topical, antifungal agents, and others. In 2019, the systemic oral azoles segment accounted for the largest share of the Europe systemic aspergillosis and systemic candidasis market. The growth of the segment attributes to the to rise in prevalence of fungal diseases is among the primary factors contributing to the dominance of the segment in the Europe systemic aspergillosis and systemic candidasis market. Additionally, the outbreak of the COVID-19 pandemic has highly affected the countries in the Europe region. Systemic aspergillosis and systemic candidasis are the types of fungal infections. Molds cause the aspergillosis infection and majorly affects the respiratory tract of an individual. It is also a severe pulmonary infection caused by Aspergillus, a common fungus that affects people with weakened immune systems or lung diseases. Moreover, severe fungal infections occur due to other health problems, including AIDS, asthma, cancer, organ transplantation, and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal treatment; however, this is often delayed or unavailable, leading to death, severe chronic illness, or blindness. For instance, according to the journal of Fungi published in March 2017, HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease, asthma, and the increasing incidence of cancers are the primary drivers of fungal infections in both developed and developing countries globally.
Furthermore, according to a study by the European Society of Clinical Microbiology and Infectious Diseases in 2019, about 43 799 cases of candidaemia were diagnosed among 1,885 271,885 persons annually. This reveals that the estimated combined incidence rate of about 3.88 per 100,000. The highest pooled incidence rate was recorded in intensive care units with a mortality rate of about 37%, about 38% in the tertiary care centres, and 37% of a mixed group of teaching and general hospitals pooled for 30 days. The incidence of candidaemia in the European population was estimated to about 79 cases per day, which is estimated 29 patients might have a fatal outcome at day 30.
Novartis AG, Sanofi, Pfizer Inc., Merck & Co., Inc., Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plc., Abbott, Cipla Inc., Enzon Pharmaceuticals, Inc, are among the prominent players present in the systemic aspergillosis and systemic candidasis market. The market players are focused on mergers and acquisitions to sustain their position in the market. For instance, in July 2018 Pfizer Inc. and Basilea Pharmaceutical Ltd. an international have entered into an agreement whereby Pfizer will be granted the exclusive commercialization rights in Europe to CRESEMBA a novel anti-fungal treatment for adult patients with diagnosed invasive aspergillosis and mucormycosis, two serious infections associated with high morbidity and mortality among immunocompromised patients.
The report segments the Europe systemic aspergillosis and systemic candidasis market as follows:
By Type
By Application
By Country
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
